WO2004044226A3 - Induction de senescence cellulaire par rupture de la cdk4 pour la suppression et la regression tumorales - Google Patents

Induction de senescence cellulaire par rupture de la cdk4 pour la suppression et la regression tumorales Download PDF

Info

Publication number
WO2004044226A3
WO2004044226A3 PCT/US2003/036037 US0336037W WO2004044226A3 WO 2004044226 A3 WO2004044226 A3 WO 2004044226A3 US 0336037 W US0336037 W US 0336037W WO 2004044226 A3 WO2004044226 A3 WO 2004044226A3
Authority
WO
WIPO (PCT)
Prior art keywords
cdk4
disruption
regression
induction
cellular senescence
Prior art date
Application number
PCT/US2003/036037
Other languages
English (en)
Other versions
WO2004044226A2 (fr
Inventor
Hiroaki Kiyokawa
Xianghong Zou
Original Assignee
Univ Illinois
Hiroaki Kiyokawa
Xianghong Zou
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Illinois, Hiroaki Kiyokawa, Xianghong Zou filed Critical Univ Illinois
Priority to AU2003287692A priority Critical patent/AU2003287692A1/en
Publication of WO2004044226A2 publication Critical patent/WO2004044226A2/fr
Publication of WO2004044226A3 publication Critical patent/WO2004044226A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes permettant d'inhiber la croissance de cellules tumorales, selon lesquelles il est prévu de mettre les cellules en contact avec un inhibiteur de Cdk4. L'invention concerne en outre des méthodes permettant de traiter des patients atteints de cancer, suspects d'être atteints de cancer ou à risque de développer un cancer, qui comprennent le traitement avec un inhibiteur de Cdk4. L'invention concerne par ailleurs des compostions pharmaceutiques permettant de traiter des patients de ce type, lesdites compostions pharmaceutiques comprenant un inhibiteur de Cdk4.
PCT/US2003/036037 2002-11-12 2003-11-12 Induction de senescence cellulaire par rupture de la cdk4 pour la suppression et la regression tumorales WO2004044226A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003287692A AU2003287692A1 (en) 2002-11-12 2003-11-12 Induction of cellular senescence by cdk4 disruption for tumor supression and regression

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42537202P 2002-11-12 2002-11-12
US60/425,372 2002-11-12

Publications (2)

Publication Number Publication Date
WO2004044226A2 WO2004044226A2 (fr) 2004-05-27
WO2004044226A3 true WO2004044226A3 (fr) 2005-02-17

Family

ID=32312979

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/036037 WO2004044226A2 (fr) 2002-11-12 2003-11-12 Induction de senescence cellulaire par rupture de la cdk4 pour la suppression et la regression tumorales

Country Status (2)

Country Link
AU (1) AU2003287692A1 (fr)
WO (1) WO2004044226A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596079A (en) * 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6221873B1 (en) * 1998-03-04 2001-04-24 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US20010047019A1 (en) * 2000-02-07 2001-11-29 Salvati Mark E. 3-Aminopyrazole inhibitors of cyclin dependent kinases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5596079A (en) * 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
US5962316A (en) * 1992-10-16 1999-10-05 Cold Spring Harbor Laboratory Cell-cycle regulatory proteins, and uses related thereto
US6221873B1 (en) * 1998-03-04 2001-04-24 Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic Cyclin dependent kinase inhibitor
US20010047019A1 (en) * 2000-02-07 2001-11-29 Salvati Mark E. 3-Aminopyrazole inhibitors of cyclin dependent kinases

Also Published As

Publication number Publication date
AU2003287692A8 (en) 2004-06-03
AU2003287692A1 (en) 2004-06-03
WO2004044226A2 (fr) 2004-05-27

Similar Documents

Publication Publication Date Title
PT1297851E (pt) Inibicao de histona-desacetilase como tratamento para hipertrofia cardiaca
WO2004039774A3 (fr) Inhibiteurs de kinesine mitotique
WO2003039460A3 (fr) Inhibiteurs de la kinesine mitotique
WO2003099211A3 (fr) Inhibiteurs de kinesine mitotique
WO2003049678A3 (fr) Inhibiteurs mitotiques de la kinesine
WO2003050064A3 (fr) Inhibiteurs de kinesine mitotique
WO2003049527A3 (fr) Inhibiteurs miotitiques de la kinesine
WO2003049679A3 (fr) Inhibiteurs mitotiques de la kinésine
WO2003050122A3 (fr) Inhibiteurs mitotiques de la kinesine
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
WO2003079973A3 (fr) Inhibiteurs de kinesine mitotique
WO2003101444A8 (fr) Composes et derives de diaryluree utilises comme inhibiteurs de chk-1 dans le traitement du cancer
WO2007016338A3 (fr) Utilisation d’inhibiteurs de la chk2 kinase pour le traitement du cancer
WO2004058148A3 (fr) Inhibiteurs de la kinesine mitotique
WO2004058700A3 (fr) Inhibiteurs de kinesine mitotique
GB0121490D0 (en) Ciompounds
MX2008015775A (es) Compuestos y composiciones para tratamiento de cancer.
WO2006031348A3 (fr) Inhibiteurs de la kinesine mitotique
TR200401316T4 (tr) Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler
WO2005118592A8 (fr) Tetrahydropyridothiophenes utilises dans le traitement anticancereux
WO2005065183A3 (fr) Inhibiteurs mitotiques de la kinesine
WO2005060960A3 (fr) Utilisation de l'histamine pour le traitement de maladies osseuses
GB0121494D0 (en) Compounds
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP